Endocrine Basis for Recurrent Pregnancy Loss

Obstetrics and Gynecology Clinics of North America

Volumn 41, Issue 1, 2014, Pages 103-112

  Ke, Raymond W ^a  

^a Fertility Associates of Memphis   (United States)

Author keywords

Hyperprolactinemia; Luteal phase defect; Polycystic ovary syndrome; Recurrent pregnancy loss; Thyroid antibodies; Thyroid disease

Indexed keywords

HYPERPROLACTINEMIA; LUTEAL PHASE DEFECT; POLYCYSTIC OVARY SYNDROME; RECURRENT PREGNANCY LOSS; THYROID ANTIBODIES; THYROID DISEASE;

ABORTION, HABITUAL; FEMALE; HUMANS; HYPERINSULINISM; HYPERPROLACTINEMIA; HYPOGLYCEMIC AGENTS; LUTEINIZING HORMONE; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREVALENCE; PROGESTINS; THYROID DISEASES; WEIGHT LOSS;

EID: 84894906447     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2013.10.003     Document Type: Review

References (52)

1. Klentzeris L.D. The role of the endometrium in implantation. Humanit Rep 1997, 12(Suppl 11):170-175.
2. Wilcox A.J., Baird D.D., Weinberg C.R. The time of implantation of the conceptus and loss of pregnancy. NEngl J Med 1999, 340:1796-1799.
3. Jones G.S. The luteal phase defect. Fertil Steril 1976, 27(4):351-356.
4. Noyes R.W., Hertig A.W., Rock J. Dating the endometrial biopsy. Fertil Steril 1950, 1:3-25.
5. Smith M.L., Schust D.J. Endocrinology and recurrent pregnancy loss. Semin Reprod Med 2011, 29:482-490.
6. Horta J.L., Fernandez J.G., de Leon B.S., et al. Direct evidence of luteal insufficiency in women with habitual abortion. Obstet Gynecol 1977, 49(6):705-708.
7. Saleh M.I., Warren M.A., Li T.C., et al. Alight microscopic morphometric study of the luminal epithelium of human endometrium during the peri-implantation period. Humanit Rep 1995, 10:1828-1832.
8. Murray M.J., Meyer W.R., Zaino R.J., et al. Acritical analysis of the accuracy, reproducibility, and clinical utility of histologic endometrial dating in fertile women. Fertil Steril 2004, 81(5):1333-1343.
9. Tulppala M., Björses U.M., Stenman U.H., et al. Luteal phase defect in habitual abortion: progesterone in saliva. Fertil Steril 1991, 56(1):41-44.
10. Lessey B.A., Fritz M.A. Defective luteal function. Estrogens and progestogens in clinical practice 1998, 437-453. W.B. Saunders, Philadelphia. J.S. Fraser, R.P. Jansen, R.A. Lobo (Eds.).
11. Li T.C., Spuijbroek M.D., Tuckerman E., et al. Endocrinological and endometrial factors in recurrent miscarriage. BJOG 2000, 107(12):1471-1479.
12. Haas D.M., Ramsey P.S. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2008, (2). CD003511.
13. Hirahara F., Andoh N., Sawai K., et al. Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials. Fertil Steril 1998, 70:246-252.
14. Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev 1997, 18:404-433.
15. Abalovich M., Gutierrez S., Alcaraz G., et al. Overt and subclinical hypothyroidism complicating pregnancy. Thyroid 2002, 12:63-68.
16. Abalovich M., Amino N., Barbour L.A., et al. Management of thyroid dysfunction during pregnancy and post partum: an Endocrine Society Clinical Practice guideline. JClin Endocrinol Metab 2007, 92(Suppl 8):S1-S47.
17. Benhadi N., Wiersinga W.M., Reitsma J.B., et al. Higher maternal TSH levels in pregnancy are associated with increased risk for miscarriage, fetal or neonatal death. Eur J Endocrinol 2009, 160(6):985-991.
18. Glinoer D. Thyroidal and immune adaptation to pregnancy: focus on maternal hypo- and hyperthyroidism. The thyroid and reproduction 2009, 36-58. Thieme, New York. J. Lazarus, V. Pirags, S. Butz (Eds.).
19. Glinoer D., Rihai M., Grün J.P., et al. Risk of subclinical hypothyroidism in pregnant women with autoimmune thyroid disorders. JClin Endocrinol Metab 1994, 79:197-202.
20. Hollowell J.G., Staehling N.W., Flanders W.D., et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): national health and nutrition examination survey (NHANES III). JClin Endocrinol Metab 2002, 87(2):489-499.
21. Stagnaro-Green A., Roman S.H., Cobin R.H., et al. Detection of at-risk pregnancy by means of highly sensitive assays for thyroid autoantibodies. JAm Med Assoc 1990, 19:1422-1425.
22. Chen L., Hu R. Thyroid autoimmunity and miscarriage: a meta-analysis. Clin Endocrinol 2011, 74:513-519.
23. Thangaratinam S., Tan A., Knox E., et al. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. BMJ 2011, 342:d2616.
24. Kaprara A., Krassas G.E. Thyroid autoimmunity and miscarriage. Hormones 2008, 7:294-302.
25. Bussen S., Steck T., Dietl J. Increased prevalence of thyroid antibodies in euthyroid women with a history of recurrent invitro fertilization failure. Humanit Rep 2000, 15(3):545-548.
26. Negro R., Formosa G., Mangieri T., et al. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. JClin Endocrinol Metab 2006, 91(7):2587-2591.
27. Reid S.M., Middleton P., Cossich M.C., et al. Interventions for clinical and subclinical hypothyroidism pre-pregnancy and during pregnancy. Cochrane Database Syst Rev 2013, (5). CD00752.
28. Mandel S.J., Larsen P.R., Seely E.W., et al. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. NEngl J Med 1990, 323(2):91-96.
29. Glueck C.J., Wang P., Goldenberg N., et al. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Humanit Rep 2002, 17(11):2858-2864.
30. Rai R., Clifford K., Regan L. The modern preventative treatment of recurrent miscarriage. Br J Obstet Gynaecol 1996, 103:106-110.
31. Ford H.B., Schust D.J. Recurrent pregnancy loss: etiology, diagnosis and therapy. Rev Obstet Gynecol 2009, 2:76-83.
32. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensu diagnostic criteria and long-term health risks related to polycysic ovary syndrome. Fertil Steril 2004, 81(1):19-25.
33. Rai R., Backos M., Rushworth F., et al. Polycystic ovaries and recurrent miscarriage - a reappraisal. Humanit Rep 2000, 15:612-615.
34. Nardo L.G., Rai R., Backos M., et al. High serum luteinizing hormone and testosterone concentrations do not predict pregnancy outcome in women with recurrent miscarriage. Fertil Steril 2002, 77:348-352.
35. Clifford K., Rai R., Watson H., et al. Does suppressing luteinising hormone secretion reduce the miscarriage rateα Results of a randomised controlled trial. BMJ 1996, 312:1508-1511.
36. Mulders A.G., Eijkemans M.J., Imani B., et al. Prediction chances for success or complications in gonadotrophin ovulation induction in normogonadotropic anovulatory infertility. Reprod BioMed Online 2003, 7:170-178.
37. van Wely M., Bayram N., van der Veen F., et al. Predicting ongoing pregnancy following ovulation induction with recombinant FSH in women with polycystic ovary syndrome. Humanit Rep 2005, 20:1827-1832.
38. Metwally M., Ong K.J., Ledger W.L., et al. Does high body mass index increase the risk of miscarriage after spontaneous and assisted conceptionα A meta-analysis of the evidence. Fertil Steril 2008, 90(3):714-726.
39. Lashen H., Fear K., Sturdee D.W. Obesity is associated with increased risk of first-trimester and recurrent miscarriage: matched case-control study. Humanit Rep 2004, 19(7):205-210.
40. Maryam K., Bouzari Z., Basirat Z., et al. The comparison of insulin resistance frequency in patients with recurrent early pregnancy loss to normal individuals. BMC Res Notes 2012, 5:133.
41. Craig L.B., Ke R.W., Kutteh W.H. Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss. Fertil Steril 2002, 78:487-490.
42. Atiomo W.U., Bates S.A., Condon J.E., et al. The plasminogen activator inhibitor system in women with polycystic ovary syndrome. Fertil Steril 1998, 69(2):236-241.
43. Glueck C.J., Wang P., Bornovali S., et al. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: assocaition with recurrent pregancy loss. Metabolism 2003, 52(12):1627-1632.
44. Sun L., Lv H., Wei W., et al. Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome. JEndocrinol Invest 2010, 33:77-82.
45. Glueck C.J., Phillips H., Cameron D., et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001, 75(1):46-52.
46. Jakubowicz D.J., Iuorno M.J., Jakubowicz S., et al. Effects of metformin on early pregnancy loss in polycystic ovary syndrome. JClin Endocrinol Metab 2002, 87(2):524-529.
47. Legro R.S., Barnhart H.X., Schlaff W.D., et al. Cooperative multicenter reproductive medicine network. Clomiphene, metformin or both for infertility in the polycystic ovary syndrome. NEngl J Med 2007, 356(6):551-566.
48. Zolghadri J., Tavana Z., Kazerooni T., et al. Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effects of metformin in these patients: a prospective clinical study. Fertil Steril 2008, 90(3):727-730.
49. Jovanovic L., Knopp H., Kim H., et al. Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancies: evidence for a protective adaptation in diabetes. Diabetes Care 2005, 28:1113-1117.
50. Mills J.L., Simpson J.L., Driscoll S.G., et al. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. NEngl J Med 1988, 319(25):1617-1623.
51. Glueck C.J., Goldenberg N., Pranikoff J., et al. Height, weight and motor-social development during the first 18 months of life in 126 infants born to 109 mother with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Humanit Rep 2004, 19(6):1323-1330.
52. Clark A.M., Ledger W., Galletly C., et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Humanit Rep 1995, 10(10):2705-2710.